title: [A case report: feasible treatment of adalimumab for Crohn disease during pregnancy].
abstract: A 33-year-old woman with Crohn disease complained of diarrhea and hematochezia from the fifth week of her third pregnancy and was hospitalized. Because her CDAI indicated 307.1 points and colonoscopy showed multiple longitudinal ulcers in the distal colon, adalimumab therapy was initiated. The CDAI had decreased to 160.0 points and the colonic ulcers improved by 22 days after beginning the administration of adalimumab. Although adalimumab therapy was continued every 2 weeks during the third trimester, fetus growth was not affected and the woman delivered a healthy child. Adalimumab should be considered as one treatment for Crohn disease during pregnancy.
authors: Department of Gastroenterology, National Hospital Organization Shiga Hospital, Japan. tujikawa@belle.shiga-med.ac.jp
authors: Tomoyuki
authors: T
authors: Tsujikawa
authors: Shigeki
authors: S
authors: Sakai
authors: Makoto
authors: M
authors: Fujii
authors: Takao
authors: T
authors: Saotome
authors: Hirotsugu
authors: H
authors: Imaeda
authors: Shigeki
authors: S
authors: Bamba
authors: Akira
authors: A
authors: Andoh
authors: Yoshihide
authors: Y
authors: Fujiyama
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab